Compare Stocks: OVID, VSTM, and ATXI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.48	$0.39	$0.15 ▼ $0.97	$1.57M	-0.18	6,851 shs	13 shs
OVID Ovid Therapeutics	$2.71 +0.7%	$2.63	$1.18 ▼ $3.11	$525.35M	0.24	1.52 million shs	1.18 million shs
VSTM Verastem	$7.99 +7.4%	$6.84	$3.43 ▼ $10.82	$673.79M	0.32	2.17 million shs	2.80 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	-29.94%	+85.39%	+49.24%	-37.17%
OVID Ovid Therapeutics	+0.74%	-1.09%	-3.21%	+16.81%	+123.97%
VSTM Verastem	+7.39%	+6.39%	+15.97%	+89.79%	-11.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.48	$0.39	$0.15 ▼ $0.97	$1.57M	-0.18	6,851 shs	13 shs
OVID Ovid Therapeutics	$2.71 +0.7%	$2.63	$1.18 ▼ $3.11	$525.35M	0.24	1.52 million shs	1.18 million shs
VSTM Verastem	$7.99 +7.4%	$6.84	$3.43 ▼ $10.82	$673.79M	0.32	2.17 million shs	2.80 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	0.00%	-29.94%	+85.39%	+49.24%	-37.17%
OVID Ovid Therapeutics	+0.74%	-1.09%	-3.21%	+16.81%	+123.97%
VSTM Verastem	+7.39%	+6.39%	+15.97%	+89.79%	-11.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	0.00	N/A	N/A	N/A
OVID Ovid Therapeutics	2.90	Moderate Buy	$6.00	121.40% Upside
VSTM Verastem	2.82	Moderate Buy	$13.83	73.13% Upside

Current Analyst Ratings Breakdown

Latest OVID, VSTM, and ATXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	VSTM Verastem	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/11/2026	OVID Ovid Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
9/11/2026	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
9/11/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
9/4/2026	VSTM Verastem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	OVID Ovid Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
8/10/2026	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$14.00 ➝ $13.00
8/7/2026	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$14.00 ➝ $12.00
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00
7/21/2026	OVID Ovid Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
OVID Ovid Therapeutics	$7.25M	73.00	N/A	N/A	$1.00 per share	2.71
VSTM Verastem	$30.91M	23.41	N/A	N/A	$0.74 per share	10.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	-$0.85	0.03	N/A	N/A	N/A	-471.57%	-296.50%	11/13/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	-240.11%	-23.64%	-20.52%	11/11/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest OVID, VSTM, and ATXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	2.70	2.70
OVID Ovid Therapeutics	0.05	12.39	12.39
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
OVID Ovid Therapeutics	72.24%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	8.60%
OVID Ovid Therapeutics	7.00%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	4	3.30 million	2.02 million	Not Optionable
OVID Ovid Therapeutics	23	195.30 million	181.63 million	Optionable
VSTM Verastem	102	90.56 million	88.81 million	Optionable

OVID, VSTM, and ATXI Headlines

Recent News About These Companies

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

2 hours ago | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of "Moderate Buy" by Analysts

September 21 at 2:28 AM | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 21 at 2:28 AM | marketbeat.com

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

September 19 at 11:52 PM | finance.yahoo.com

Wolfe Research Begins Coverage on Verastem (NASDAQ:VSTM)

September 19 at 1:54 AM | americanbankingnews.com

Wall Street Zen Downgrades Verastem (NASDAQ:VSTM) to Sell

September 19 at 1:14 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) Downgraded by Wall Street Zen to "Sell"

September 19 at 1:11 AM | marketbeat.com

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

September 18, 2026 | theglobeandmail.com

Verastem (NASDAQ:VSTM) Coverage Initiated by Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

September 14, 2026 | streetinsider.com

Verastem (NASDAQ:VSTM) Earns Buy Rating from BTIG Research

September 13, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Earns "Buy" Rating from HC Wainwright

September 13, 2026 | americanbankingnews.com

Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM

September 12, 2026 | marketbeat.com

Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright

September 11, 2026 | marketbeat.com

Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target

September 11, 2026 | tipranks.com

BTIG Research Reaffirms "Buy" Rating for Verastem (NASDAQ:VSTM)

September 11, 2026 | marketbeat.com

Opaleye Management Inc. Purchases New Position in Verastem, Inc. $VSTM

September 11, 2026 | marketbeat.com

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

September 8, 2026 | zacks.com

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

September 8, 2026 | businesswire.com

Verastem (NASDAQ:VSTM) Stock Rating Upgraded by Wall Street Zen

September 5, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Sees Strong Trading Volume - Should You Buy?

September 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OVID, VSTM, and ATXI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

$0.48 0.00 (0.00%)

As of 09/18/2026

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Ovid Therapeutics NASDAQ:OVID

$2.71 +0.02 (+0.74%)

As of 09/21/2026 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Verastem NASDAQ:VSTM

$7.99 +0.55 (+7.39%)

As of 09/21/2026 04:00 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OVID, VSTM, and ATXI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OVID, VSTM, and ATXI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OVID, VSTM, and ATXI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OVID, VSTM, and ATXI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Ovid Therapeutics NASDAQ:OVID

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OVID, VSTM, and ATXI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OVID, VSTM, and ATXI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OVID, VSTM, and ATXI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OVID, VSTM, and ATXI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Ovid Therapeutics NASDAQ:OVID

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools